Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France

Table 4 Summary of scenario and sensitivity analysis (total cohort)

Scenario	Bevacizumab plus paclitaxel		Paclitaxel alone				ICER, EUR per QALY gained
Scenario	Life years	QALYs	Costs	Life years	QALYs	Costs	ICER, EUR per QALY gained
Survival estimates
Lower bound of 95% CI	2.996	2.008	54,163	2.269	1.521	26,874	56,064
Upper bound of 95% CI	3.193	2.151	57,041	2.457	1.654	28,634	57,173
Allowing sharing of vials	2.993	2.006	53,206	2.272	1.523	26,925	54,423
100% patients remaining progression-free^a	2.993	1.970	54,315	2.272	1.550	26,925	65,196
Discount rate, future costs
1.5% per annum	2.993	2.006	56,526	2.272	1.523	28,226	58,607
6% per annum	2.993	2.006	52,746	2.272	1.523	25,992	55,404
Discount rate, clinical outcomes
1.5% per annum	3.162	2.113	54,315	2.372	1.586	26,925	51,226
6% per annum	2.874	1.931	54,315	2.201	1.479	26,925	60,650
Time horizon
5 years	2.491	1.687	47,859	2.025	1.367	23,778	75,226
15 years	3.077	2.068	54,954	2.299	1.544	27,063	53,258

^a100% patients in both arms remaining progression-free (i.e. for the calculation of the calculation of the utility value all patients are considered to be responders)
CI confidence interval, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year

ISSN: 1471-2407